Parasite expelling composition and application thereof in yak breeding

Abstract

The invention provides a parasite expelling composition and application thereof in yak breeding, the parasite expelling composition comprises albendazole and myrobalan acid, through the synergistic effect of albendazole and myrobalan acid, on one hand, the myrobalan acid inhibits the activity of liver microsome metabolic enzymes, prolongs the half-life period of albendazole, improves the bioavailability and optimizes the pharmacokinetic process, on the other hand, the myrobalan acid inhibits the activity of liver microsome metabolic enzymes, and on the other hand, the myrobalan acid inhibits the activity of liver microsome metabolic enzymes; on the other hand, the two act on parasite tubulin synthesis and a body surface biofilm structure respectively to form double-target synergistic killing, so that the parasite expelling effect is remarkably improved; chebulinic acid can repair gastrointestinal mucosa, regulate flora balance, enhance appetite and effectively counteract irritant injury of albendazole to gastrointestinal tracts; the parasite expelling rate reaches 95% or above, the average daily gain reaches 369 g / d, and no obvious influence is caused to the blood system and liver and kidney functions of yaks; the composition has the characteristics of simple formula, gastrointestinal protection and convenience in administration, is adaptive to the current breeding situation of high parasite infection rate of yaks in plateau pasturing areas, and has a good industrial application prospect.

Description

Technical Field

[0001] This application relates to the fields of yak breeding and veterinary deworming technology, and more specifically, to a deworming composition and its application in yak breeding. Background Technology

[0002] Yaks are a unique livestock species native to the Qinghai-Tibet Plateau and surrounding high-altitude regions of my country, and are one of the important sources of income for local herders. Because their raising is primarily grazing, yaks are highly susceptible to internal and external parasites. Common internal parasites include nematodes, flukes, and tapeworms, while external parasites mainly include mites, ticks, and tussock fly larvae. These parasites deprive yaks of nutrients, damage the gastrointestinal mucosa, leading to stunted growth, emaciation, and weakened immunity. In severe cases, they can cause complications and even death. Furthermore, they can transmit zoonotic diseases, causing significant economic losses for yaks and threatening human health.

[0003] Currently, deworming of yaks mainly relies on chemical agents, commonly including benzimidazoles (such as albendazole) and macrolides (such as ivermectin). Albendazole is widely used to prevent and treat nematode, tapeworm, and liver fluke diseases in yaks. However, long-term use of this type of drug alone has the following drawbacks: First, it easily leads to drug resistance in parasites, gradually reducing its deworming effect; second, chemical deworming drugs can irritate and damage the gastrointestinal mucosa of yaks, disrupting the intestinal flora balance and causing functional disorders such as loss of appetite, diarrhea, and indigestion, thus affecting the growth, development, and production performance of yaks, with particularly significant effects on young and weak yaks.

[0004] Traditional Chinese medicine (TCM) and its active ingredients possess multiple functions, including anthelmintic, anti-inflammatory, immune-regulating, and gastrointestinal mucosal protection. They also exhibit low toxicity and are less prone to drug resistance, demonstrating unique advantages in the field of veterinary deworming. While existing technologies have attempted to combine TCM compound prescriptions with chemical anthelmintics, the complex composition and unstable content of active ingredients in TCM compound prescriptions make precise dosage control difficult. Furthermore, antagonistic effects may exist between different components, affecting both anthelmintic efficacy and gastrointestinal protection. In contrast, single-herb TCM has clearly defined components and controllable dosage, enabling more precise synergistic effects and gastrointestinal protection.

[0005] Therefore, given the limitations of existing yak deworming drugs, such as limited deworming effect, easy development of drug resistance, and damage to gastrointestinal function, and considering the current situation of high natural parasite infection rate of yaks in high-altitude pastoral areas, there is an urgent need to develop a combination drug composition based on chemical deworming drugs and combined with specific Chinese herbal monomers. This composition can significantly improve the deworming effect, delay the development of drug resistance, effectively protect the gastrointestinal function of yaks, and be adapted to the physiological characteristics of yaks in the high-altitude and cold environment. Summary of the Invention

[0006] To address the aforementioned problems, this invention provides an anthelmintic composition and its application in yak farming. It addresses the shortcomings of existing chemical anthelmintics, such as the development of parasite resistance and decreased efficacy with long-term single use of albendazole, as well as irritation and damage to the yak's gastrointestinal tract, leading to decreased appetite and digestive disorders. This composition significantly broadens the anthelmintic spectrum and increases the deworming rate to over 95% through a synergistic mechanism of albendazole inhibiting parasite microtubule synthesis and chebulic acid disrupting the parasite's biomembrane structure and paralyzing its neuromuscular system. Simultaneously, chebulic acid slows down the liver's metabolism of albendazole, prolonging the drug's half-life, improving bioavailability, optimizing its pharmacokinetic process in yaks, and effectively protecting the gastrointestinal mucosa, regulating gut microbiota balance, enhancing appetite, and counteracting the gastrointestinal irritation side effects of single anthelmintics.

[0007] In a first aspect, the present invention provides an anthelmintic composition comprising albendazole and chebulic acid. The chebulic acid is a single effective monomeric component extracted from the dried, mature fruit of the Tibetan medicinal herb Terminalia chebula, with a monomer purity ≥95%.

[0008] Chebulic acid and albendazole exhibit a bidirectional synergistic effect in the gastrointestinal environment of yaks. On one hand, chebulic acid, as a natural organic acid, enhances the stability of tight junctions in mucosal epithelial cells by regulating the gastrointestinal mucosal barrier function, repairing micro-damage to the mucosal surface that may be caused by albendazole, and maintaining the integrity of the mucosal barrier. On the other hand, chebulic acid can regulate the peristaltic rhythm of gastrointestinal smooth muscle, optimize the secretion of digestive juices and rumination function, and alleviate the inhibitory effect of albendazole on gastrointestinal motility while ensuring the full absorption of albendazole, thereby improving stress responses such as loss of appetite and indigestion.

[0009] On the other hand, chebulic acid promotes the proliferation of beneficial bacteria and inhibits the colonization of harmful bacteria by regulating the balance of the gastrointestinal microecology, providing a suitable intestinal microenvironment for the stable absorption of albendazole. Meanwhile, albendazole, while exerting its anthelmintic effect, reduces mechanical damage and inflammatory stimulation of the gastrointestinal mucosa by parasites, working together with chebulic acid to maintain the stability of mucosal structure and function. The two work synergistically to form a positive cycle of anthelmintics, mucosal protection, microecological regulation, and maintenance of digestive function. This achieves highly effective anthelmintics while effectively ensuring the stability of the physiological functions of the yak's gastrointestinal tract, making it particularly suitable for calves whose gastrointestinal function is not yet fully developed and pregnant yaks in special physiological states.

[0010] Preferably, the pharmaceutical excipients are also included; the pharmaceutical excipients are selected from one or more of starch, microcrystalline cellulose, and magnesium stearate, and are mixed in any proportion.

[0011] Preferably, the composition comprises the following components in parts by weight: 1-4 parts albendazole, 8-20 parts chebulic acid, and 5-12 parts pharmaceutical excipients. The preferred weight ratio of the anthelmintic composition is: 2 parts albendazole, 12 parts chebulic acid monomer, 7 parts starch, and 1 part magnesium stearate. This ratio provides optimal synergistic effect, balancing anthelmintic efficacy, gastrointestinal protection, and pharmacokinetic optimization, while also resulting in the best tablet forming effect.

[0012] In a second aspect, the present invention provides a method for preparing an insect repellent composition, comprising the following steps: S1: Albendazole, chebulic acid and pharmaceutical excipients are pulverized and sieved separately to obtain fine powder for later use; S2: First mix albendazole fine powder and chebulic acid fine powder, then add pharmaceutical excipient fine powder and continue mixing until homogeneous; S3: Compress the uniformly mixed powder into tablets and coat them with a film.

[0013] Preferably, the albendazole is pulverized and passed through a 100-mesh sieve, and the chebulic acid and pharmaceutical excipients are pulverized and passed through an 80-mesh sieve.

[0014] Preferably, the albendazole fine powder and chebulic acid powder are mixed in a three-dimensional motion mixer for 10-20 min, and the remaining pharmaceutical excipients are added and the mixture is continued for 8-15 min.

[0015] Thirdly, the present invention provides the use of an anthelmintic composition in the preparation of a medicament for improving the anthelmintic effect in yaks.

[0016] Preferably, the therapeutic dose of the anthelmintic composition is: 0.2 mg / kg body weight for albendazole and 1.2 mg / kg body weight for chebulic acid, once daily for 3-4 consecutive days.

[0017] Preferably, the preventive dosage of the anthelmintic composition is: 0.1 mg / kg body weight for albendazole and 0.6 mg / kg body weight for chebulic acid, administered once every 30 days.

[0018] In summary, the present invention has at least one of the following beneficial technical effects: 1. This invention significantly optimizes the pharmacokinetic process of albendazole in yaks through the combined application of chebulic acid and albendazole. Chebulic acid acts on the gastrointestinal mucosal epithelial cells of yaks, promoting the rapid absorption of albendazole. Simultaneously, by inhibiting the activity of hepatic microsomal metabolic enzymes, it delays the metabolic conversion of albendazole technical to albendazole sulfoxide, prolonging the drug half-life (t1 / 2) to 17.2 h and increasing bioavailability to 90.2%, thus maintaining an effective therapeutic concentration of albendazole at the target site in yaks for a longer period. Compared with albendazole alone, this invention achieves superior anthelmintic efficacy while reducing drug dosage, thus reducing drug waste and medication costs.

[0019] 2. This invention achieves a significant improvement in anthelmintic efficacy through the dual-target synergistic effect of albendazole and chebulic acid. Albendazole kills adult and larval worms by inhibiting the synthesis of microtubule protein in parasites and blocking energy metabolism; chebulic acid disrupts the biomembrane structure on the parasite's surface, paralyzes the parasite's nervous system and muscle tissue, causing it to lose its ability to adhere to the gastrointestinal mucosa, and simultaneously inhibits egg development. The synergistic effect of these two drugs broadens the anthelmintic spectrum and achieves complete eradication of both worms and eggs. Experimental results show that the anthelmintic rate of this invention is over 95%, an improvement of more than 15% compared to albendazole alone, effectively delaying the development of parasite resistance and solving the industry problem of declining anthelmintic efficacy due to long-term use of single drugs.

[0020] 3. This invention, through the combination of chebulic acid and other ingredients, effectively counteracts the irritant damage to the gastrointestinal tract of yaks and its inhibitory effect on gastrointestinal motility caused by albendazole. Chebulic acid, as a natural organic acid, can repair damaged gastrointestinal mucosal barriers, regulate the rhythm of gastrointestinal smooth muscle peristalsis, improve rumination function and digestive juice secretion, and simultaneously regulate the balance of intestinal flora, promoting the proliferation of beneficial bacteria. After applying this invention, the appetite of yaks significantly improved during deworming, the incidence of adverse gastrointestinal reactions was greatly reduced, and the average daily weight gain reached 369 g / d, which is within the reasonable range of routine daily weight gain for yaks in clinical practice. This represents a 64.7% increase compared to the control group (224 g / d) treated with albendazole alone, achieving a dual effect of deworming and growth maintenance. It is particularly suitable for weak groups such as calves and pregnant yaks. Attached Figure Description

[0021] To more clearly illustrate the technical solutions of the embodiments of this application, the drawings used in the description of the embodiments of this application will be briefly introduced below. Obviously, the drawings described below are only some embodiments of this application. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0022] Figure 1 The blood drug concentration-time curves of the experimental group and the control group provided in Example 2 of this application are shown. Detailed Implementation

[0023] The technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. The following description of at least one exemplary embodiment is merely illustrative and is in no way intended to limit the present invention or its application or use. Based on the embodiments of the present invention, any product that is the same as or similar to the present invention, derived by any person under the guidance of the present invention or by combining the features of the present invention with other prior art, falls within the protection scope of the present invention. Furthermore, all other embodiments obtained by those skilled in the art without inventive effort are within the protection scope of the present invention.

[0024] Specific experimental steps or conditions are not specified in the embodiments; they can be performed according to the conventional experimental steps or conditions described in the prior art. Reagents and other instruments used, unless otherwise specified, are all commercially available conventional reagent products. Furthermore, the accompanying drawings are merely illustrative diagrams of the embodiments of the present invention and are not necessarily drawn to scale. The same reference numerals in the drawings denote the same or similar parts, and therefore, repeated descriptions of them will be omitted. Some block diagrams shown in the drawings are functional entities and do not necessarily correspond to physically or logically independent entities.

[0025] Techniques, methods, and devices known to those skilled in the art may not be discussed in detail, but where appropriate, such techniques, methods, and devices should be considered part of this specification.

[0026] In the description of this invention, it should be understood that the use of terms such as "first" and "second" to define components is merely for the purpose of distinguishing the corresponding components. Unless otherwise stated, the above terms have no special meaning and therefore should not be construed as limiting the scope of protection of this invention.

[0027] Furthermore, the technical features involved in the different embodiments of the present invention described below can be combined with each other as long as they do not conflict with each other.

[0028] To enable those skilled in the art to better understand this application, the following embodiments are provided to illustrate in detail an insect repellent composition provided in this application and its application in yak farming.

[0029] Example Example 1: Preparation of the composition tablet The anthelmintic composition tablets of the present invention are prepared according to the following preferred weight ratio: 2 parts albendazole, 12 parts chebulic acid monomer, 7 parts starch, and 1 part magnesium stearate.

[0030] Albendazole technical grade drug was pulverized and passed through a 100-mesh sieve to obtain a fine powder for later use. Terminalia chebulic acid monomer, starch, and magnesium stearate were pulverized separately and passed through an 80-mesh sieve for later use. The albendazole fine powder and terminalia chebulic acid monomer powder were added to a three-dimensional motion mixer and mixed for 15 minutes to ensure thorough and uniform mixing of the core active ingredients. Then, starch and magnesium stearate were added, and mixing continued for 10 minutes to ensure uniform composition without layering or clumping. The uniformly mixed powder was placed in a tableting machine and compressed into tablets weighing 0.6 g each. These tablets were then film-coated and, after passing quality inspection, stored in sealed bottles of 100 tablets each.

[0031] Example 2 Pharmacokinetic Study This embodiment aims to investigate the pharmacokinetic properties of the anthelmintic composition tablets in yaks and evaluate the effect of chebulic acid on the absorption, distribution, metabolism, and excretion of albendazole.

[0032] Twelve healthy yaks were randomly divided into two groups of six each, with half male and half female. The experimental group was administered tablets prepared in Example 1 of this invention, with albendazole at 0.2 mg / kg body weight and chebulic acid at 1.2 mg / kg body weight; the control group was administered albendazole tablets alone, with albendazole at 0.2 mg / kg body weight. Both groups were administered orally. Blood samples were collected before administration and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, and 48 hours after administration. The concentrations of albendazole and its active metabolites in plasma were determined using high-performance liquid chromatography (HPLC), and pharmacokinetic parameters were calculated. The pharmacokinetic parameters of albendazole in each group of yaks are shown in Table 1. The blood concentration-time curves for the experimental and control groups are shown in Table 1. Figure 1 As shown.

[0033] Table 1. Pharmacokinetic parameters of albendazole in yaks of each group

[0034] The results above show that, compared with the albendazole-only control group, although the peak plasma concentration of the tablets in the experimental group of this invention was lower, the half-life was significantly prolonged, the bioavailability was greatly improved, and the area under the curve was significantly increased. These results indicate that chebulic acid can delay the hepatic metabolism of albendazole, prolong the drug's residence time in the body, optimize the absorption, distribution, and metabolism of albendazole, and significantly improve the drug's bioavailability.

[0035] Example 3: In vitro microsomal metabolic inhibition assay This embodiment investigates the effect of chebulic acid on the activity of yak liver microsomal metabolic enzymes through in vitro co-incubation experiments, evaluates the inhibitory effect of chebulic acid on the metabolic transformation process of albendazole, and reveals the potential mechanism by which the composition of the present invention optimizes the pharmacokinetics of albendazole.

[0036] Liver tissue was collected from yaks, and liver microsomes were prepared by ultracentrifugation. The liver microsomes were co-incubated with albendazole technical grade (final concentration 100 μg / mL). The experimental group also received chebulic acid monomer (final concentration 12 μg / mL), while the control group received no chebulic acid. Samples were taken at 0 h, 0.25 h, 0.5 h, 1 h, 2 h, 3 h, and 4 h after incubation. The concentrations of albendazole technical grade and its main active metabolite, albendazole sulfoxide, in the system were determined by high-performance liquid chromatography (HPLC). Three replicates were used for each group, and the average value was calculated. The concentrations of albendazole technical grade and albendazole sulfoxide in the samples at different time points are shown in Table 2.

[0037] Table 2. Concentration changes of albendazole and albendazole sulfoxide in the in vitro co-incubation system

[0038] Example 4: Insect repellent effect test Ninety naturally infected yaks were randomly divided into three groups of 30 each, with no significant difference in initial parasite infection levels among the groups. The experimental groups were administered tablets prepared in Example 1 of this invention orally at a dose of 0.2 mg / kg body weight of albendazole and 1.2 mg / kg body weight of chebulic acid. The control group received only albendazole tablets orally at a dose of 0.2 mg / kg body weight of albendazole. The blank control group received an equal volume of blank tablets. All groups received the medication once daily for three consecutive days. Fecal samples were collected from each group on days 7 and 14 after administration. Parasite eggs were detected using the saturated saline flotation and sedimentation methods, and the egg conversion rate was calculated. Simultaneously, necropsies were performed on the yaks slaughtered after the experiment, and the number of parasites in the gastrointestinal tract and liver was counted to calculate the parasite eradication rate. The deworming effects of each group are shown in Table 4.

[0039] Table 4 Comparison of egg conversion rate and parasite elimination rate in yaks after drug administration in each group

[0040] Table 4 shows that the egg conversion rate in the experimental group reached 95.8% and 97.5% at 7 and 14 days after administration, respectively, and the parasite elimination rate reached 96.2% and 98.0%, respectively, both significantly higher than those in the single control group (egg conversion rate 83.2% and parasite elimination rate 83.5% at 14 days after administration) and the blank control group (P < 0.01). The deworming effect in the experimental group remained stable, with no downward trend observed at 14 days after administration compared to 7 days, and no recurrent infections were observed; while the deworming effect in the single control group was relatively limited, with approximately 15% or more of the parasites remaining.

[0041] The above results demonstrate that the anthelmintic composition tablets of the present invention, through the synergistic effect of albendazole and chebulic acid, can effectively eliminate internal and external parasites in yaks, with both the egg conversion rate and the parasite elimination rate reaching over 95%, significantly superior to albendazole alone. This composition is suitable for the current clinical breeding situation of yaks in high-altitude pastoral areas with a high natural parasite infection rate (over 80%), and can achieve complete prevention and control of parasites.

[0042] Example 5: Weight Gain Detection Test Ninety healthy yaks were selected and randomly divided into three groups of 30 yaks each, with no significant difference in initial weight among the groups. The experimental groups were administered tablets prepared in Example 1 of this invention orally at a dose of 0.2 mg / kg body weight of albendazole and 1.2 mg / kg body weight of chebulic acid. The control group was administered albendazole tablets orally at a dose of 0.2 mg / kg body weight of albendazole. The blank control group received an equal volume of blank tablets. All groups were administered the medication once daily for three consecutive days as one course of treatment. The weight of the yaks in each group was measured before administration (initial), 21 days after administration, and 42 days after administration. The average weight gain and average daily weight gain were calculated. The results of the weight gain in each group are shown in Table 5.

[0043] Table 5 Comparison of weight gain among different groups of yaks

[0044] Table 5 shows that the average weight gain of the yaks in the experimental group after 42 days of drug administration was 15.5±1.2 kg, with an average daily weight gain of 369±25.6 g / d, which is within the clinically normal daily weight gain range for yaks (360~400 g / d). The average daily weight gain of the control group was 224±21.8 g / d, significantly lower than that of the experimental group (P<0.01), indicating that the use of albendazole alone inhibited gastrointestinal motility due to gastrointestinal stimulation, resulting in a significant decrease in daily weight gain. The average daily weight gain of the blank control group was 152±19.5 g / d, the lowest among the three groups.

[0045] The above results indicate that the anthelmintic composition tablets of the present invention, through the combination with chebulic acid, effectively counteract the irritant damage to the gastrointestinal tract and the inhibitory effect on gastrointestinal motility caused by albendazole, protecting the gastrointestinal function of yaks, improving their appetite, and enabling yaks to maintain normal growth and development during deworming. Compared with the control group alone (albendazole), the experimental group showed an average daily weight gain increase of 64.7%; compared with the blank control group, the increase was 142.8%, achieving the dual effects of deworming and growth maintenance.

[0046] Example 6 Safety Testing Test Ninety healthy yaks were randomly divided into three groups of 30 each. The experimental group received the tablets prepared in Example 1 of this invention, administered orally at a dose of 0.2 mg / kg body weight of albendazole and 1.2 mg / kg body weight of chebulic acid. The control group received only albendazole tablets, administered orally at a dose of 0.2 mg / kg body weight of albendazole. The blank control group received an equal volume of blank tablets. All groups received the medication once daily for three consecutive days, constituting one course of treatment. Fasting venous blood samples were collected from each group 21 days after administration. Complete blood count (CBC) indicators were measured using an automated hematology analyzer, and liver and kidney function indicators were measured using an automated biochemical analyzer. The test results for each group were compared with baseline values ​​before administration, and differences between groups were assessed. The CBC and liver and kidney function test results for each group 21 days after administration are shown in Table 6.

[0047] Table 6. Comparison of blood routine and liver and kidney function indicators of yaks in each group 21 days after drug administration.

[0048] Based on the experimental results of the above embodiments, the combined medication tablets of this invention, combined with the clinical breeding characteristics of yaks, demonstrate significant and practical application advantages: excellent pharmacokinetic characteristics, significantly improving the bioavailability of albendazole, prolonging its half-life, optimizing the drug's metabolic process in vivo, allowing a limited dose of anthelmintic to exert its maximum efficacy, and adapting to the physiological characteristics of poor drug absorption in high-altitude yaks; significant and clinically appropriate anthelmintic effect, suitable for the current breeding situation of over 80% high parasite infection rate in yaks in high-altitude pastoral areas, with egg conversion rate and parasite removal rate both reaching over 95%, far exceeding that of albendazole alone, and the anthelmintic effect is continuous and stable, achieving complete parasite prevention and control, and reducing recurrent infections; outstanding gastrointestinal protection and growth maintenance effects, effectively counteracting the irritation and inhibition of gastrointestinal motility of single anthelmintics, with the experimental group achieving an average daily weight gain of 369 g / d, within the reasonable range of clinically routine daily weight gain for yaks (360~400 g / d), compared to the single control group (224 g / d). The growth rate of veterinary deworming drugs increased by 64.7% compared to the control group (152 g / d), and by 142.8% compared to the control group (152 g / d). This not only avoids growth retardation caused by deworming but also ensures normal growth during the deworming period. The drug has extremely high safety, with all blood routine and liver and kidney function test indicators meeting the clinical safety requirements for veterinary deworming drugs without causing bodily damage. There was no significant difference compared to the control group, and it had no obvious toxic side effects on yaks. The tablet dosage form is convenient for administration, with a neat shape, easy storage and transportation. It can be administered orally or mixed with feed without the need for special equipment. It is fully in line with the actual scenario of extensive breeding in plateau pastoral areas and has extremely strong clinical promotion and industrial application value.

[0049] The various embodiments in this specification are described in a progressive manner, with each embodiment focusing on the differences from other embodiments. The same or similar parts between the various embodiments can be referred to each other.

[0050] Although preferred embodiments of the present application have been described, those skilled in the art, upon learning the basic inventive concept, can make other changes and modifications to these embodiments. Therefore, the appended claims are intended to be interpreted as including the preferred embodiments as well as all changes and modifications falling within the scope of the embodiments of the present application.

[0051] Finally, it should be noted that in this document, relational terms such as "first" and "second" are used only to distinguish one entity or operation from another, and do not necessarily require or imply any such actual relationship or order between these entities or operations. Furthermore, the terms "comprising," "including," or any other variations thereof are intended to cover non-exclusive inclusion, such that a process, method, article, or terminal device that comprises a list of elements includes not only those elements but also other elements not expressly listed, or elements inherent to such a process, method, article, or terminal device. Without further limitations, an element defined by the phrase "comprising one..." does not exclude the presence of other identical elements in the process, method, article, or terminal device that includes said element.

[0052] The above provides a detailed description of the deworming composition provided in this application and its application in yak breeding. Specific examples have been used to illustrate the principles and implementation methods of this application. The description of the above embodiments is only for the purpose of helping to understand the method and core ideas of this application. At the same time, for those skilled in the art, there will be changes in the specific implementation methods and application scope based on the ideas of this application. Therefore, the content of this specification should not be construed as a limitation of this application.

Claims

1. An insect repellent composition, characterized in that, Including albendazole and chebulic acid.

2. The insect repellent composition according to claim 1, characterized in that, It also includes pharmaceutical excipients; the pharmaceutical excipients are selected from one or more of starch, microcrystalline cellulose, and magnesium stearate, and are mixed in any proportion.

3. The insect repellent composition according to claim 1, characterized in that, It consists of the following components in parts by weight: albendazole 1-4 parts, chebulic acid 8-20 parts, and pharmaceutical excipients 5-12 parts.

4. A method for preparing the insect repellent composition according to any one of claims 1 to 3, characterized in that, Includes the following steps: S1: Albendazole, chebulic acid and pharmaceutical excipients are pulverized and sieved separately to obtain fine powder for later use; S2: First mix albendazole fine powder and chebulic acid fine powder, then add pharmaceutical excipient fine powder and continue mixing until homogeneous; S3: Compress the uniformly mixed powder into tablets and coat them with a film.

5. The method for preparing the insect repellent composition according to claim 4, characterized in that, The albendazole was pulverized and passed through a 100-mesh sieve, while the chebulic acid and pharmaceutical excipients were pulverized and passed through an 80-mesh sieve.

6. The method for preparing the insect repellent composition according to claim 4, characterized in that, The albendazole fine powder and chebulic acid powder are mixed in a three-dimensional motion mixer for 10-20 min, and the remaining pharmaceutical excipients are added and the mixture is continued for 8-15 min.

7. The use of the anthelmintic composition as described in any one of claims 1 to 3 in the preparation of a medicament for improving the anthelmintic effect in yaks.

8. The application according to claim 7, characterized in that, The therapeutic dose of the anthelmintic composition is as follows: albendazole at a dose of 0.2 mg / kg body weight and chebulic acid at a dose of 1.2 mg / kg body weight, once daily for 3-4 consecutive days.

9. The application according to claim 7, characterized in that, The preventative dosage of the anthelmintic composition is as follows: albendazole at a dose of 0.1 mg / kg body weight and chebulic acid at a dose of 0.6 mg / kg body weight, administered once every 30 days.

Images